Data S1. Evaluation of Fluoxetine in Overall Survival of GBM Patients Using Electronic Medical Records from The IBM MarketScan Dataset

Published: 29 September 2021| Version 1 | DOI: 10.17632/5gww3pgbj3.1
Contributors:
,
,
,

Description

The potential therapeutic benefit of fluoxetine with standard of care treatment was evaluated in GBM patients cohort using electronic medical records from the IBM MarketScan Dataset (2003-2017). GBM Patients with two other SSRIs, citalopram and escitalopram, were used as controls. The dataset includes six figures: data S1 Figures 1-6 which provide more details of the data overview, data extraction pipeline, exclusion criteria, enrichment for GBM patients, statistical analyses, and results.

Files

Categories

Glioblastoma Multiforme, Brain Cancer Survival

License